Best of IGCS 2022 Annual Global Meeting-Master Session: Cervical Cancer – Paving the Way to a Treatment Shift in Cervical Cancer

Video Transcription

Video Summary

In this video, the speakers discussed the clinical implications of HPV-independent cervical cancers for screening programs. These cancers are rare, often presenting at advanced stages, and may not be effectively detected through HPV screening. Developing specific screening protocols for these cases is challenging due to their small number. Further research is needed to determine the best approach.<br /><br />Dr. Kohler discussed the challenges and changes in Brazil's screening and detection program. He emphasized the need for improving the quality of Pap smear tests and adopting DNA tests for more accurate screening.<br /><br />Dr. Obermeier addressed the importance of reconsidering language and thinking around non-HPV cervical cancers. These rare cases have significant implications for research and the current screening program.<br /><br />Dr. Tiwari talked about the role of immunotherapy in cervical cancer treatment. Pembrolizumab has recently been approved for recurrent or metastatic cervical cancer patients. Ongoing trials are exploring immunotherapy in combination with chemotherapy and targeted therapies.<br /><br />Lastly, Dr. LaRusso discussed antibody drug conjugates (ADCs) for cervical cancer treatment. She focused on tesadodimab vedotin, which has been approved and highlighted its mechanism of action and the results of clinical trials.<br /><br />Overall, the speakers provided insights into the current and future treatment options for cervical cancer, including improving screening methods, immunotherapy, and the use of antibody drug conjugates.

Keywords

clinical implications

HPV-independent cervical cancers

screening programs

rare cancers

advanced stages

specific screening protocols

challenges

further research

improving Pap smear tests

DNA tests

non-HPV cervical cancers

immunotherapy

cervical cancer treatment

Pembrolizumab

antibody drug conjugates